SynAging´s AD Solutions
SynAging has established a target validation and drug discovery platform for Alzheimer´s disease that is based on its proprietary misfolded-protein-aggregate-induced disease models, causing neurodegeneration and neuroinflammation in vitro and in vivo. The main advantadge in comparison to most labs around the world is SynAging's technology of creating the misfolded protein aggregates with entirely physicochemical methods and no use of crosslinkers, helper proteins, or other contaminats of the natural protein. Highly consistent neurotoxicity of the aggregates is achieved by the stable change of the 3D protein conformation and aggregation of the misfolded natural proteins, as is expected to happen in diseased patients.
For many drug discovery companies assay times are critical. Therefore SynAging's services are optimized for fast performance and scalability of the experiments by using wilde type (WT) mice for the models, which are readily available and best represent the sporadic onset of disease in patient. The timings for the amyloid beta oligomer induced models is given as an example below.